Valuation: Rekvina Laboratories Limited

Market Cap 59Cr 61.64L 53.82L 50.57L 46.19L 86.69L 86.63L 6.06Cr 2.34Cr 30Cr 2.31Cr 2.26Cr 97Cr P/E 2025
-19.6x
P/E 2026 -85.6x
Enterprise Value 60Cr 63.16L 55.15L 51.82L 47.34L 88.83L 88.78L 6.21Cr 2.4Cr 31Cr 2.37Cr 2.32Cr 99Cr EV / Sales 2025
-
EV / Sales 2026 1,83,72,546x
Free-Float
-
Yield 2025 *
-
Yield 2026 -
12/09 Rekvina Laboratories Limited Announces Resignation of Amit Mukesh Shah from Director, Effective September 11, 2026 CI
12/09 Rekvina Laboratories Limited Announces Resignation of Amit Mukesh Shah from Managing Director, Effective September 11, 2026 CI
02/09 Rekvina Laboratories Limited Announces Resignation of Deepak Khandelwal as Company Secretary & Compliance Officer, Effective September 2, 2026 CI
13/08 Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
13/08 Rekvina Laboratories Limited Announces Appointment of Surbhit Shah as Chairman of the Board CI
14/07 Surbhit Mukesh Shah, the managing director of Rekvina Laboratories Limited, Amit Mukesh Shah, the director of Rekvina Laboratories Limited and Dhruvalkumar Patel completed the acquisition of an additional 23.22% stake in Rekvina Laboratories Limited for INR 14.41 million. CI
21/05 Rekvina Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
16/03 Rekvina Laboratories Limited entered into agreement to acquire Radiant Parenterals Limited from Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel, Krima Surbhit Shah and Ami Amit Shah for approximately INR 140 million. CI
16/03 Surbhit Mukesh Shah and Amit Mukesh Shah, the directors of Rekvina Laboratories Limited and Dhruvalkumar Patel proposed to acquire an additional 47.94% stake in Rekvina Laboratories Limited for INR 28.9 million. CI
11/03 Rekvina Laboratories Limited announced that it expects to receive INR 4.6 million in funding CI
06/02 Rekvina Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
29/01 Rekvina Laboratories Limited Announces the Resignation of Chetanbhai Jayantibhai Patel as Non- Executive Independent Director and from Membership in Various Committees, Effective from 29 January 2026 CI
09/01 Rekvina Laboratories Limited Announces Resignation of Dhruvalkumar Jayantilal Patel as Non-Executive Independent Director, Effective January 9, 2026 CI
1 day-1.56%
1 week-10.77%
Current month+6.53%
1 month+27.04%
3 months+41.52%
6 months+61.34%
Current year+1,077.78%
1 week 52.77
Extreme 52.77
57.19
1 month 41
Extreme 41
59.4
Current year 6.75
Extreme 6.75
59.4
1 year 6.75
Extreme 6.75
59.4
3 years 6.75
Extreme 6.75
59.4
5 years 4.18
Extreme 4.18
59.4
10 years 3.6
Extreme 3.6
59.4
Manager TitleAgeSince
Director of Finance/CFO 43 02/09/2024
Director TitleAgeSince
Director/Board Member 24 22/05/2024
Director/Board Member 43 02/09/2024
Chairman 31 05/10/2024

Financials

2025 2026
Net sales - 12.65 0.13 0.12 0.11 0.1 0.19 0.19 1.3 0.5 6.46 0.5 0.49 20.84
Net income -13.71L -14.34T -12.52T -11.77T -10.75T -20.17T -20.16T -1L -54.42T -7L -53.87T -52.68T -22.58L -25.47L -26.65T -23.27T -21.86T -19.97T -37.48T -37.45T -3L -1L -13.01L -1L -97.87T -41.94L
Net Debt 22.18L 23.2T 20.26T 19.04T 17.39T 32.64T 32.62T 2L 88.05T 11.33L 87.14T 85.23T 36.52L 1.46Cr 2L 1L 1L 1L 2L 2L 14.99L 6L 74.43L 6L 6L 2.4Cr
Date Price Change Volume
22/26/22 ₹53.00 -1.56% 3,782
21/26/21 ₹53.84 -1.98% 844
18/26/18 ₹54.93 -2.00% 1,600
17/26/17 ₹56.05 -1.99% 51
16/26/16 ₹57.19 -1.99% 1,007
  1. Stock Market
  2. Stocks
  3. VINRKLB Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!